65,437 trials
Neurogenic Urinary Bladder
Primary: Number of Patients With Detrusor Leak Point Pressure (LPP) < 40 cm H2O — 23; 23; 28; 34 participants — p=1.00
Hemophilia A
Primary: Investigator Hemostatic Efficacy Assessment 8 Hours Post Infusion — 1.86 Units on a scale
Hydronephrosis · Neurogenic Bladder
Primary: Number of Participants With a Decrease From Baseline ≥ 1 in the Society of Fetal Urology (SFU) Grade of Hydronephrosis — 2; 5; 3; 1 participants
Hemophilia A
Primary: Percentage of Participants With Less Than 2 Joint Bleeds During the 9-month Treatment Period — 72.7; 84.6; 75.0 Percentage of participants
End-Stage Renal Disease (ESRD)
Primary: Percent of Subjects Whose Hemoglobin (Hgb) Decreases by a Total of 1.0 Grams/ Deciliter (g/dL) (or More) From Baseline on Each of Two Successive Measurements. — 5; 6; 5…
Renal Transplantation
Primary: Number of Participants With the Occurrence of Treatment Failures at 6 Months Post-transplantation — 20; 16 Number of participants
Hemophilia A
Primary: Mean Number of Bleeding Episodes Per Patient Year — 13.41 episodes per year
Healthy
Primary: Period 1: AUC0-3d — 8680; 7651; 6465; 12258 pg/mL*h
Essential Hypertension
Primary: Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to End of Study (Week 8) — -13.5; -16.5; -12.6; -17.0 mm Hg
Rhinitis, Allergic, Perennial · Allergic Rhinitis
Primary: Mean Change From Baseline Over the Entire Treatment Period in the Daily Reflective Total Nasal Symptom Score (rTNSS) — -4.226; -2.728 Points on a scale — p=<0.0001
HIV Infections
Primary: Time From Randomization to Virologic Failure or Death for Participants Who Had SD NVP Exposure Prior to Study Entry — 12; 60; 12; 84 weeks — p=<0.001
Stage 2 Systolic Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure After 6 Weeks — 166.8; 168.5; 135.5; 142.5 mmHg
Recurrent Small-cell Lung Cancer (SCLC) · Lung Cancer, Small Cell
Primary: Percentage of Participants With Progression-free Survival (PFS) at 3 Months — 65 percentageof participants — p=0.017
Acute Myelogenous Leukemia · Chemotherapy-induced Nausea and Vomiting
Primary: Number of Patients With Complete Response — 11; 15; 18 participants
Off Pump Coronary Artery Bypass Surgery
Primary: Number of Patients Required Allogenic Red Blood Cells Transfusion — 37; 54 participants — p=<0.05